Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix < sup > TM < /sup > and Prevenar13 < sup > TM) < /sup > ) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian children

CONCLUSION: The reduced dose schedule (1 + 1) of PCV13 results in significant VT-carriage reduction in the second year of life. Immune protection provided by 1 + 1 schedules of PCV10 and PCV13 in the second year of life is comparable to WHO-recommended 3-dose schedules.PMID:37045679 | DOI:10.1016/j.vaccine.2023.04.008

Source: Vaccine - April 12, 2023 Category: Allergy & Immunology Authors: Anand Kawade Girish Dayma Aditi Apte Nilima Telang Meenakshi Satpute Emma Pearce Lucy Roalfe Rakesh Patil Yanyun Wang Navideh Noori Arun Gondhali Sanjay Juvekar Assaf P Oron Sonali Sanghavi David Goldblatt Ron Dagan Ashish Bavdekar Source Type: research